Transforming
Anemia Management

Rockwell Medical is a biopharmaceutical company dedicated to improving patients' lives through effective treatment of iron deficiency and anemia.

Our Company Vision

Our vision is to establish a new standard of care for patients suffering with iron deficiency and iron deficiency anemia.

Iron deficiency anemia afflicts a subset of the two billion people worldwide who are nutritionally iron deficientREF. Approximately 10 million people are iron deficient in the United States, including 5 million who have iron deficiency anemia.

Learn more

Our Platform Technology

Ferric Pyrophosphate Citrate (FPC)

Our innovative therapeutic was developed to replace iron loss in patients with anemia in an entirely different way. Our unique and differentiated molecule, Ferric Pyrophosphate Citrate (FPC), provides a novel mechanism of action with a physiologic approach. FPC donates iron directly to circulating transferrin making it immediately bioavailable for critical body processes, which allows the body to use the iron in a physiologic manner.

Ferric Pyrophosphate Citrate in blood

FPC is introduced to the blood

FPC for iron deficiency

FPC donates iron directly and completely to transferrin – providing bioavailable iron for red blood cell production

avoids iron sequestration

FPC avoids iron sequestration by macrophages in liver and spleen

hemoglobin formation

Transferrin-bound iron immediately delivered to bone marrow for hemoglobin formation

FPC for maintaining hemoglobin

FPC delivers 100% bioavailable iron to maintain hemoglobin

Ferric Pyrophosphate Citrate in blood

FPC is introduced to the blood

arrow
FPC for iron deficiency

FPC donates iron directly and completely to transferrin – providing bioavailable iron for for red blood cell production

arrow
avoids iron sequestration

FPC avoids iron sequestration by macrophages in liver and spleen

arrow
hemoglobin formation

Transferrin-bound iron immediately delivered to bone marrow for hemoglobin formation

arrow
FPC for maintaining hemoglobin

FPC delivers the desired amount of iron maintenance over time

This novel approach to the treatment of iron deficiency and anemia has the potential for application in many disease states.

Investor Center

Access our investor center to learn about our strategies to deliver value for the patients we serve, the medical community, our employees and shareholders.

Access Now
investor center

Latest News

arrow left
arrow right

August 3, 2022

Rockwell Medical to Release Second Quarter 2022 Financial Results on Monday, August 15

WIXOM , Mich.  , Aug. 3, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced that it will release its financial

Read more

June 22, 2022

Rockwell Medical Provides Corporate and Clinical Update

- Closes $7.5 Million Second Tranche Investment from DaVita -  $30 Million in Total Capital Raised This Quarter - Receives Additional Feedback from FDA on its IND Application WIXOM, Mich. , June 22, 2022 /PRNewswire/ --  Rockwell Medical , Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated

Read more

June 22, 2022

Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer

WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and Chief

Read more

June 7, 2022

Rockwell Medical Closes $15 Million Financing from Leading Healthcare Investor

WIXOM, Mich. , June 7, 2022 /PRNewswire/ -- Rockwell Medical , Inc. (Nasdaq: RMTI) has closed the previously announced  $15 Million in financing, consisting of $12 Million in a Registered Direct Offering, and $3 Million in a private investment in public equity (PIPE), both priced at-market, with

Read more

June 1, 2022

Rockwell Medical Regains Compliance with Nasdaq Listing Requirements

WIXOM , Mich.  , June 1, 2022 /PRNewswire/ --  Rockwell Medical , Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ)  on May 31, 2022

Read more